Literature DB >> 17468759

PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit.

Takashi Tanaka1, Michael J Grusby, Tsuneyasu Kaisho.   

Abstract

Activation of transcription factor NF-kappaB in the innate immune system is tightly regulated to prevent excessive inflammatory responses. How NF-kappaB activation is terminated, however, is not fully understood. Here we report that PDLIM2 negatively regulated NF-kappaB activity, acting as a nuclear ubiquitin E3 ligase targeting the p65 subunit of NF-kappaB. PDLIM2 bound to p65 and promoted p65 polyubiquitination. In addition, PDLIM2 targeted p65 to discrete intranuclear compartments where polyubiquitinated p65 was degraded by the proteasome. PDLIM2 deficiency resulted in larger amounts of nuclear p65, defective p65 ubiquitination and augmented production of proinflammatory cytokines in response to innate stimuli. Our findings delineate a pathway by which PDLIM2 terminates NF-kappaB activation through intranuclear sequestration and subsequent degradation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468759     DOI: 10.1038/ni1464

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  134 in total

Review 1.  Selectivity of the NF-{kappa}B response.

Authors:  Ranjan Sen; Stephen T Smale
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-14       Impact factor: 10.005

2.  TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and p65/RelA protein and represses NF-kappaB activation.

Authors:  Tiziana Zotti; Antonio Uva; Angela Ferravante; Mariangela Vessichelli; Ivan Scudiero; Michele Ceccarelli; Pasquale Vito; Romania Stilo
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

3.  Monoubiquitination of nuclear RelA negatively regulates NF-κB activity independent of proteasomal degradation.

Authors:  Karin Hochrainer; Gianfranco Racchumi; Sheng Zhang; Costantino Iadecola; Josef Anrather
Journal:  Cell Mol Life Sci       Date:  2012-01-20       Impact factor: 9.261

Review 4.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 5.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

6.  Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense.

Authors:  Kei-ichiro Arimoto; Kenji Funami; Yasushi Saeki; Keiji Tanaka; Katsuya Okawa; Osamu Takeuchi; Shizuo Akira; Yoshiki Murakami; Kunitada Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-19       Impact factor: 11.205

7.  CD4 memory T cells develop and acquire functional competence by sequential cognate interactions and stepwise gene regulation.

Authors:  Tomohiro Kaji; Atsushi Hijikata; Akiko Ishige; Toshimori Kitami; Takashi Watanabe; Osamu Ohara; Noriyuki Yanaka; Mariko Okada; Michiko Shimoda; Masaru Taniguchi; Toshitada Takemori
Journal:  Int Immunol       Date:  2015-12-29       Impact factor: 4.823

Review 8.  Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease.

Authors:  Xuetao Cao
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

9.  A genome-wide siRNA screen reveals positive and negative regulators of the NOD2 and NF-κB signaling pathways.

Authors:  Neil Warner; Aaron Burberry; Luigi Franchi; Yun-Gi Kim; Christine McDonald; Maureen A Sartor; Gabriel Núñez
Journal:  Sci Signal       Date:  2013-01-15       Impact factor: 8.192

10.  PPARγ is an E3 ligase that induces the degradation of NFκB/p65.

Authors:  Yongzhong Hou; France Moreau; Kris Chadee
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.